Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
351 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Currently Recruiting (92)
  • Closed (634)

Medical Condition

  • Show all (833)
  • Autoimmune Disorders (1)
  • Blood Disorders (4)
  • (-) Cancer (726)
    • Bladder Cancer (14)
    • Brain Cancer (25)
    • Breast Cancer (70)
    • Gastrointestinal (16)
    • Gynecologic Cancer (28)
    • Head and Neck Cancer (4)
    • Kidney Cancer (8)
    • Leukemia (75)
    • Liver Cancer (10)
    • Lung Cancer (62)
    • Lymphoma (45)
    • Multiple Myeloma (30)
    • Pancreatic Cancer (22)
    • Prostate Cancer (36)
    • Sarcoma (25)
    • Skin Cancer (30)
    • Solid Tumors (42)
    • Thyroid Cancer (1)
    • Uveal Melanoma (7)
  • COVID-19 (Coronavirus) (1)
  • Diabetes (2)
  • Ear, Nose and Throat (1)
  • Endocrine & Metabolic Disease (1)
  • Gastrointestinal and Digestive Diseases (2)
  • Healthy Volunteers (8)
  • Liver Disease (1)
  • Neurological Disorders (31)
  • Obesity (1)
  • Obstetrics & Gynecology (6)
  • Pediatrics (42)
  • Psychiatric Disorders (1)
  • Surgery (1)
  • Transplant (3)
  • Urology (1)
Displaying 1 - 200 of 726

Study of 68Ga-FAP-2286 and 177Lu-FAP-2286 in Patients with Advanced Cancer

Condition: Cancer
Investigator: Ryan Moy, MD
Status: Currently Recruiting
The purpose of this study is to test the safety of the experimental drugs called 68Ga-FAP-2286 and 177Lu-FAP-2286. 68Ga-FAP-2286 is an imaging agent that targets a certain protein which has been found in certain tumors called Fibroblast activation protein (FAP). Imaging using 68Ga-FAP-2286 will determine if participants are eligible to receive the…
Read More

Study of ASP3082 in Patients with Advanced Cancer with a KRAS G12D Mutation

Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose of this study is to find out if ASP3082 is effective and safe as a treatment in advanced cancers with KRAS G12D mutation. ASP3082 may work by directing proteins found in your body to block the growth of cancer cells. This is the first study where ASP3082 is being tested in humans.…
Read More

Study of RMC-6236 in Patients with Solid Tumors with a KRAS Mutation

Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose of this study is to test an experimental drug called RMC-6236 (the study drug) for solid tumor cancer with a KRAS mutation. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals, and this blocking…
Read More

Study of JNJ-86974680 Alone or in Combination with Cetrelimab and Radiotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Currently Recruiting
The purpose of this study is to find out if JNJ-86974680 taken by itself or together with Cetrelimab and radiotherapy can cause side effects which are unexpected or unwanted reactions. This is the first time that JNJ-86974680 is being used in people. Radiotherapy is also part of the study treatment and not part of your standard of care. JNJ-86974680 and…
Read More

Study of JNJ-78278343 in Patients with Advanced Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
You are being invited to take part in a research study that includes studying JNJ-78278343 in subjects with prostate cancer. This is an investigational drug which means that this is a new approach for the treatment of people who have prostate cancer. The main purpose of this study is to find a…
Read More

Study of TransCon IL-2 / vs. TransCon TLR7/8 Agonist in Patients with Gynecologic Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Currently Recruiting
The purpose of this research is to learn about what effects, both good and/or bad, an experimental drug called TransCon IL-2 / has when given by itself or in combination with pembrolizumab, SOC chemotherapy, or TransCon TLR7/8 Agonist, or in combination with pembrolizumab and SOC chemotherapy. TransCon IL-2 / works by blocking the reproduction and spread of…
Read More

Study of RMC-6291 and RMC 6236 in Patients with Solid Tumors

Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose of this study is to test a combination of 2 new drugs called RMC-6291 and RMC 6236 (the study drugs). RMC-6291 and RMC-6236 are new investigational (ie, experimental) drugs, which means that they are not approved by the United States (US) Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC…
Read More

The Cancer of the Pancreas Screening-5 Study (CAPS5 Study)

Condition: Cancer / Pancreatic Cancer
Investigator: Fay Kastrinos, MD
Status: Currently Recruiting
Pancreatic cancer is a deadly disease and the best hope for improving the chances of survival is to find it early. Some patients, called "high-risk", have an inherited predisposition to pancreatic cancer. Certain medical centers have started programs where high-risk patients undergo testing, such…
Read More

Study of AZD9574 in Patients with Brain Cancer

Condition: Cancer / Brain Cancer
Investigator: Maria Diaz Ordonez, MD
Status: Currently Recruiting
The main purpose of this study is to determine a dose of AZD9574 that is safe and tolerable (does not cause side effects that could prevent people from taking the drug) when given alone or in combination with temozolomide. The study will also evaluate how much of the study drug is in your blood at various times. In addition, the action of the study drug…
Read More

Study of Durvalumab in Patients with Non-Small Cell Lung Cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose this study to learn more about if a medication called durvalumab will work and be safe for the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) with certain genetic changes when given in combination with tremelimumab and standard chemotherapy. Additionally,…
Read More

Study of Radiotherapy in Patients with Low-Risk HER2-Positive Breast Cancer (HERO*)

Condition: Cancer / Breast Cancer
Investigator: Eileen Connolly, MD, PhD
Status: Currently Recruiting
This study is being done to answer the following question: Is treatment with HER2-targeted therapy without radiation therapy as good as the usual treatment of radiation and HER2-targeted therapy in patients with HER2-positive breast cancer who have had surgery, chemotherapy, and HER2-targeted therapy? This study is being done…
Read More

Identification of Targets for Cancer Treatment

Condition: Cancer
Investigator: Andrea Califano, PhD
Status: Currently Recruiting
The purpose of this protocol is to describe the acquisition and analysis of tumor tissue samples, with the goal of identifying master regulator genes that may be targeted by existing FDA-approved drugs or late-stage experimental compounds, either individually or in combination. Should we be able to predict such therapeutic targets, drug screening will be…
Read More

IRONMAN: International Registry for Men with Advanced Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The main goal of a research study is to learn things to help patients in the future. The decision to join or not join the research study will not cause you to lose any medical benefits. If you decide not to take part in this study, your doctor will continue to treat you. The purpose of this study is to learn more about prostate …
Read More

Chemo4METPANC: Combination of Chemotherapy, Motixafortide, and Cemiplimab in Patients with Pancreatic Cancer

Condition: Cancer / Pancreatic Cancer
Investigator: Gulam Manji, MD, PhD
Status: Currently Recruiting
The purpose of this study is to determine if a combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing tumor size and prolonging life in patients with advanced pancreas cancer. The treatment consists of both immunotherapy (cemiplimab and motixafortide) and chemotherapy (…
Read More

Study of Bethanechol in Combination with Chemotherapy for Patients with Pancreatic Cancer

Condition: Cancer / Pancreatic Cancer
Investigator: Susan Bates, MD
Status: Currently Recruiting
The purpose of this study is to determine whether the drug, bethanechol, could potentially be used in combination with chemotherapy regimen gemcitabine and nab-paclitaxel and surgery to decrease the chance of the cancer coming back after it is removed. Animal models have shown that treatment with bethanechol can inhibit…
Read More

Impact of Aromatase Inhibitors on Daily Activities for Individuals with Breast Cancer

Condition: Cancer / Breast Cancer
Investigator: Rochelle Mendonca, PhD
Status: Currently Recruiting
The Department of Occupational Therapy at Columbia University will be conducting research to understand the impact of aromatase inhibitors (AIs) on performing everyday activities, like bathing and making meals, for women diagnosed with breast cancer. The purpose of this study is to understand how functional performance is…
Read More

Study of T-DM1 in Combination with Tucatinib for Patients with HER2-Positive Breast Cancer

Condition: Cancer / Breast Cancer
Investigator: Julia McGuinness, MD
Status: Currently Recruiting
This study is being done to answer the following question: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone at preventing your cancer from returning? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your…
Read More

Study of Osimertinib in Patients with Non-Small Cell Lung Cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Currently Recruiting
This study will compare the effectiveness of osimertinib alone to the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene for the epidermal growth factor receptor (EGFR). Osimertinib alone is the usual treatment for metastatic…
Read More

Study of IDE397 in Patients with Advanced Solid Tumors

Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
IDE397 is an investigational drug, which has not been approved by health authorities for the treatment of people with your medical condition. It is currently not "on the market" (available for you to receive a prescription for and/or to buy) in any country. The main goals of the study are to determine the safety, tolerability, and effects of IDE397 used as…
Read More

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (LOXO-LNC-24001)

Condition: Cancer / Bladder Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is to determine whether using LY4052031 in a type of cancer that may have tumor cells that express a protein called Nectin-4 is safe and how well the cancer responds to the study drug. LY4052031 has not been approved by the US Food and Drug Administration (FDA). This is…
Read More

Study of REGN4018 Alone or in Combination with Cemiplimab in Patients with Ovarian Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Currently Recruiting
The main purpose of this study is to learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or in combination with cemiplimab to research subjects with ovarian cancer without too many side effects. The study will also look at the levels of REGN4018 and/or cemiplimab in the body and measure…
Read More

Study of ASP2138 in Patients with Stomach or Pancreatic Cancer

Condition: Cancer / Pancreatic Cancer
Investigator: Ryan Moy, MD
Status: Currently Recruiting
The goal of this study is to see if a study drug called ASP2138 is safe and effective for people diagnosed with tumors known to have Claudin (CLDN) 18.2 expression. CLDN is a group of proteins seen in gastric-specific, gastroesophageal junction (GEJ) or pancreatic cancer types. The study will also see how ASP2138 is processed…
Read More

Study of GLSI-100 in Female Patients with Breast Cancer

Condition: Cancer / Breast Cancer
Investigator: Julia McGuinness, MD
Status: Currently Recruiting
The purpose of this research is to test how well an investigational study drug (medication), GLSI-100, can prevent your cancer from coming back. The research study will also collect information about the safety of the medication. The research will also study how the medication works and who responds the best to the medication…
Read More

Study of JNJ-87189401 in Combination with JNJ 78278343 in Patients with Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The purpose of this study is to find out the side effects of JNJ-87189401 given in combination with JNJ-78278343 to patients with metastatic castration-resistant prostate cancer, and to find which doses of the two study drugs when given in combination cause the least side effects. The study will also look at how long JNJ-…
Read More

Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The purpose of this study is to determine the safety, tolerability (how your body reacts to the drug) and effectiveness of REGN5678 which will be given alone first and then be given in combination with cemiplimab. Neither REGN5678 nor Cemiplimab is FDA-approved to treat your type of cancer. Cemiplimab is approved by the FDA…
Read More

Study of RLY-2608 in Patients with Breast Cancer

Condition: Cancer / Breast Cancer
Investigator: Julia McGuinness, MD
Status: Currently Recruiting
This research study is designed to learn about the safety of an experimental (investigational) drug called RLY-2608, also called the study drug, when given to individuals who have been diagnosed with metastatic (spread to other areas of the body) or unresectable (cannot be removed surgically) cancers and have at least one…
Read More

Addinex-Opioid Dispenser for Post-Op Pain in Cancer Patients

Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Currently Recruiting
The purpose of this study is to evaluate the use of the Addinex device, a time-release medication dispenser designed to assist with medication adherence, in cancer patients undergoing cancer-related surgery that require pain control with opioids after the surgery.
Read More

Comparing Investigational Surgery to Laparotomy After Chemotherapy in Women with Epithelial Ovarian Cancer (EOC)

Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Currently Recruiting
The goal of this clinical research study is to compare the outcomes of minimally invasive surgery (the investigational surgery) to laparotomy (the current standard of care) in women with Epithelial Ovarian Cancer (EOC) who receive chemotherapy before and after surgery. Researchers want to learn if one surgery can prevent the…
Read More

Study of Autogene Cevumeran & Atezolizumab Alone or in Combination with mFOLFIRINOX in Patients with Resected Pancreatic Cancer (PDAC)

Condition: Cancer / Pancreatic Cancer
Investigator: Gulam Manji, MD, PhD
Status: Currently Recruiting
The purpose of this study is to compare the effects, good or bad, of autogene cevumeran plus atezolizumab and mFOLFIRINOX compared with mFOLFIRINOX (standard of care chemotherapy) alone on patients with resected pancreatic ductal adenocarcinoma (PDAC). In this study, the participant will get either the combination of autogene cevumeran plus atezolizumab and…
Read More

Liquid biopsy and radiomics for liver cancer surveillance

Condition: Cancer / Liver Cancer
Investigator: Elizabeth Verna, MD
Status: Currently Recruiting
This study aims to use new technology involving molecular and imaging tests to help detect liver cancer early in patients. Participants enrolled will participate in it for approximately 5 years. The purpose of this study is to determine if an experimental drug, INT-787, is safe and effective in patients who are hospitalized…
Read More

Study of ONC-392 in Combination with PLUVICTO in Male Patients with Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The main purpose of the study is to determine whether the study drug, ONC-392, together with a standard of care drug PLUVICTO (Lutetium Lu 177 Vipivotide Tetraxetan), are safe and well tolerated, and whether two drugs are effective in treating prostate cancer, in comparison with the standard of care PLUVICTO alone. ONC-392 has…
Read More

Study of IDE196 in Patients with Solid Tumors

Condition: Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is to evaluate the safety profile of IDE196 (an investigational drug), in enrolled subjects to find out if it is safe and possibly helpful in patients with certain cancers such as metastatic uveal melanoma, cervical cancer, lung cancer,…
Read More

Study of Whole-Food Plant-Based Diet (WFPBD) to Control Weight in Overweight/Obese Men with Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The purpose of this study is to assess the efficacy of a home-delivered whole-food plant-based diet (WFPBD) intervention in promoting weight loss in overweight or obese men with prostate cancer receiving androgen deprivation therapy (ADT), as compared to general nutritional counseling only. Another purpose is to assess how…
Read More

Study of STK-012 Alone or in Combination with Pembrolizumab (KEYTRUDA) in Patients with Advanced Solid Tumors

Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Currently Recruiting
The main purpose of this study is to determine the highest dose of STK-012 that can be given safely alone and in combination with a standard dose of pembrolizumab in subjects with advanced solid tumors, this will be assessed in the dose escalation phase of the study. In the dose expansion phase of the study, the highest dose of STK-012 that can be safely…
Read More

Study of T Plex in Patients with Advanced or Metastatic Solid Tumors

Condition: Cancer
Investigator: Brian Henick, MD
Status: Currently Recruiting
The purpose of the study is to learn if the study treatments TSC-204-A0201, TSC 200-A020, and TSC-204-C0702 alone or in combination, referred to as T-Plex, are safe and effective in treating your type of cancer. T-Plex has not yet been approved by the Food and Drug Administration (FDA). This is a first-in-human study, which…
Read More

Study of Zimberelimab in Patients with Advanced Pancreatic Cancer who are Eligible for Surgery

Condition: Cancer / Pancreatic Cancer
Investigator: Gulam Manji, MD, PhD
Status: Currently Recruiting
The main goal of this study is to find out if treatment with zimberelimab and stereotactic body radiation therapy alone or in combination with quemliclustat, with or without etrumadenant, given before surgery is safe and if it can further increase the immune response against the tumor.
Read More

Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Condition: Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
This purpose of this study is to test the effectiveness of cabozantinib with nivolumab and ipilimumab in rare genitourinary cancers that have no standard treatment options.
Read More

Study Comparing Survival of Patients Monitored with Serum Tumor Marker Directed Disease Versus Usual Care in Metastatic Breast Cancer

Condition: Cancer / Breast Cancer
Investigator: Melissa Accordino, MD
Status: Currently Recruiting
The purpose of this study is to determine if overall survival of patients monitored with serum tumor marker direct disease monitoring (STMDDM) is as good as the overall survival of patients monitored with the usual care.
Read More

Study of ACR-368 (Prexasertib) in Patients with Ovarian Carcinoma, Endometrial Adenocarcinoma, or Urothelial Carcinoma

Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Currently Recruiting
In this research study, an investigational medication named ACR-368 (also known as prexasertib) is being tested for the treatment of ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma. In this study, ACR-368 is being tested when it is given alone (called monotherapy) and when it is combined with low doses of a chemotherapy medication…
Read More

Study of Defactinib & Avutometinib in Patients with Stomach Cancer

Condition: Cancer / Gastrointestinal
Investigator: Ryan Moy, MD
Status: Currently Recruiting
There are two main types of stomach cancer based on the appearance under the microscope: intestinal-type and diffuse-type. Some stomach cancers also have a mix of intestinal-type and diffuse-type (mixed type). You are being invited to take part in this research study because you have been…
Read More

Clinical Trial Screening Tool to Address Cancer Health Disparities

Condition: Cancer
Investigator: Katherine Crew, MD
Status: Currently Recruiting
The overall objective of this protocol is to determine if such a screening tool within NCORP can further its research agenda focused on addressing healthcare disparities and increasing clinical trial accrual, especially among minority and under-served populations.
Read More

Study of SGN-B6A in Advanced Solid Tumors

Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose of this study is to study SGN-B6A alone, with pembrolizumab, or with pembrolizumab and one of the chemotherapy drugs (cisplatin or carboplatin). The sponsor wants to find out what its side effects are and if it works for specific types of cancer. It is not yet known if SGN-B6A alone or with other drugs is better or…
Read More

Collecting and growing patient tumor and blood cells from extra tissue to learn about cancer and test new drugs

Condition: Cancer
Investigator: Bret Taback, MD
Status: Currently Recruiting
The purpose of this research study is to obtain samples for research purposes from tests performed for clinical care or for research indications on other research protocols.
Read More

Study to Predict Your Therapeutic Response (I-SPY 2 Trial)

Condition: Cancer / Breast Cancer
Investigator: Meghna Trivedi, MD
Status: Currently Recruiting
The primary purpose of this trial is to determine whether adding new drugs to the standard initial cancer treatments for breast cancer increases the probability there will be no residual disease (cancer cells left after many attempts to remove the…
Read More

Study of Vaccine (GEN-009) in Adult Patient with Melanoma, NSCLC, Head and Neck Cancer, Bladder Cancer, or Kidney Cancer

Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
This is a research study for a vaccine called GEN-009. The main purpose of this study is to obtain information on the safety of GEN-009 and how it may activate the immune system to fight cancer. GEN-009 is a personalized vaccine. Each vaccine is made specifically for each person in the study. The vaccine is made after taking…
Read More

Study of BLU-222 Alone or in Combination with Other Cancer Therapy for Patients with Advanced Cancer

Condition: Cancer
Investigator: Julia McGuinness, MD
Status: Closed
This first-in-human study will evaluate the recommended dose, safety, and effects (good and bad) of an experimental drug, BLU-222, either alone or in combination with therapies approved for some types of cancer, including carboplatin, ribociclib, and fulvestrant, to find out if these are safe and effective ways to treat…
Read More

Study of MRT-2359 in Patients with Solid Tumors

Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose of this study is to evaluate the safety and confirm the best dose in humans for an investigational drug called MRT-2359 in subjects with solid tumors and diffuse large B-cell lymphoma. Investigational means the study drug has not been approved for the treatment of participants with cancer by the Food and Drug…
Read More

COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors

Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this clinical trial is to find a safe and tolerated dose of the study treatment COM701 in combination with BMS-986207 and nivolumab for the treatment of advanced solid tumors. These drugs are being developed to fight cancer by using your immune system to fight the cancer cells (…
Read More

Exploratory Biopsy Sample Study of Metastatic Cancer

Condition: Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is an exploratory biopsy sample study. Its purpose is to better understand why your metastatic cancer has progressed and stopped responding to checkpoint inhibitors. The information gained from this study may be valuable for understanding the mechanisms that cause resistance to immunotherapy.…
Read More

Evaluating the Efficacy & Safety of Autogene Cevumeran + Nivolumab VS Nivolumab Alone for High-Risk Muscle-Invasive Urothelial Carcinoma

Condition: Cancer / Bladder Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
This study is testing a drug called autogene cevumeran in combination with nivolumab, a cancertreatment drug known for treating bladder cancer. The purpose of this study is to compare the effects, good or bad, of autogene cevumeran plus nivolumab versus nivolumab on patients with Muscle Invasive…
Read More

The Janus Rectal Cancer Trial

Condition: Cancer / Gastrointestinal
Investigator: Yoanna Pumpalova, MD
Status: Currently Recruiting
This study is being done to answer the following question: Can we increase the clinical complete response rate (tumor disappears by exam, endoscopy, and imaging) by adding a 3rd drug (irinotecan) to the standard chemotherapy regimens known as FOLFOX or CAPOX, given following long-course chemoradiation for patients with locally advanced rectal…
Read More

Study of Sonocloud 9 in Patients with Glioblastoma (GBM)

Condition: Cancer / Brain Cancer
Investigator: Brian Gill, MD
Status: Currently Recruiting
The purpose of this study is to see if the implantable device, Sonocloud 9, is effective getting chemotherapy to better reach your tumor compared to receiving standard-of-care chemotherapy Temozolomide and Lomustine and to see how safe and tolerable the device is. Sonocloud 9 works by making the blood-brain barrier (BBB) more permeable (allowing liquids or…
Read More

Study of PF-07799544 in Patients with Solid Brain Tumors

Condition: Cancer / Brain Cancer
Investigator: Aya Haggiagi, MD
Status: Currently Recruiting
The purpose of this study is to learn about the safety (the impact of the study drug on your body) and the effects of study drug PF-07799544 for specific types of cancer on the body and to find the best dose for treating certain cancers. For BRAF (B-raf proto-oncogene serine/threonine kinase)…
Read More

Smartphone App for Cancer Medication Adherence

Condition: Cancer
Investigator: Melissa Accordino, MD
Status: Closed
Many patients with metastatic cancer experience frustration with the large number and complex scheduling of their medications. This study will help us find out how much pill burden exists in patients with advanced cancer, and how a smartphone app can help patients take their medications as their…
Read More

Study of Drug (XmAb20717) in Subjects with Advanced Solid Tumors (DUET-2) - Melanoma, Breast Cancer, Lung Cancer, Stomach Cancer

Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
This research study will learn more about the drug, XmAb20717. XmAb20717 is designed to activate your own cells to kill your tumor. The primary purposes of this research study are to: determine the safety and tolerability of XmAb20717, see if XmAb20717 works in treating specific tumors , learn about the side effects from XmAb20717.…
Read More

Study of XmAb808 in Combination with Pembrolizumab in Patients with Advanced Cancer

Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to assess whether an investigational drug, called XmAb808, given in combination with pembrolizumab, has any effects on your cancer, to determine the best dose of XmAb808 to treat your cancer, and if it is safe and well-tolerated. XmAb808 is an investigational drug…
Read More

A registry to investigate certain breast cancer diagnosis tests and treatment decisions in Chinese breast cancer patients

Condition: Cancer / Breast Cancer
Investigator: Margaret Chen-Seetoo, MD
Status: Closed
The purpose of this registry study is to assess information obtained from the Agendia Breast Cancer Suite of diagnostic tests and other clinical information to study ways to assist in breast cancer diagnosis and treatment decisions in Chinese patients. The Agendia Breast …
Read More

Safety Study of PBCAR0191 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia

Condition: Cancer
Investigator: Ran Reshef, MD
Status: Currently Recruiting
The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR0191 to treat certain types of cancers. PBCAR0191 is a new investigational treatment for certain types of cancer of the blood, such as leukemia and lymphoma. It is made from a type of blood cells…
Read More

Study of ASP2138 in Patients with Stomach or Pancreatic Cancer

Condition: Cancer / Gastrointestinal
Investigator: Ryan Moy, MD
Status: Currently Recruiting
The goal of this study is to see if a study drug called ASP2138 is safe and effective for people diagnosed with tumors known to have Claudin (CLDN) 18.2 expression. CLDN is a group of proteins seen in gastric-specific, gastroesophageal junction (GEJ) or pancreatic cancer types. The study will also see how ASP2138 is processed…
Read More

Study of DB-1311 in Patients with Solid Tumors

Condition: Cancer
Investigator: Brian Henick, MD
Status: Currently Recruiting
DB-1311 (study drug) is an investigational antibody-drug conjugate (antibody that guides the study drug to cancer cells) composed of an anti-B7-H3 (a protein associated with worse overall survival and drug resistance) antibody and P1021 (slows DNA replication in cancer cells). "Investigational"…
Read More

Study of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma (PCNSL)

Condition: Cancer / Brain Cancer
Investigator: Fabio Iwamoto, MD
Status: Currently Recruiting
The purpose of this study is to learn the effects of the investigational new drug, tirabrutinib, when given for the treatment of PCNSL. Investigational new drug means a drug that has not been approved as a marketed product (that is, available to be prescribed or sold) by the United States (US) Food and Drug Administration (FDA). Tirabrutinib acts by…
Read More

Study of LNS8801 Alone or in Combination with Pembrolizumab in Patients with Advanced Cancer

Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
This study is being done to determine if a new investigational drug, LNS8801, is safe and helpful in patients with cancer that have not improved and where there are no additional standard treatment options. LNS8801 is an agonist of the G protein-coupled estrogen receptor (GPER), meaning that it can bind to this protein and…
Read More

A study for patients with cancer of the ovary, fallopian tube, or primary peritoneal cancer using study drug AZD1775

Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
This study is for women with one of the following cancers, cancer of the ovary, fallopian tube or peritoneum and you had previous treatment with carboplatin or cisplatin. The purpose of this research study is to find a different treatment for platinum-resistant TP53-mutated high-grade serous (HGS…
Read More

Study of COM701 Alone and in Combination with Nivolumain in Patients with Advanced Solid Tumors (Breast Cancer/Ovarian Cancer/Lung Cancer)

Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
The main purposes of this research study are: to find a safe and tolerated dose of the study drug COM701 alone and in combination with nivolumab; and to measure the amount of COM701 that is in the blood at different times after it is given. This study is for people with advanced cancer (solid tumor) that no longer responds to…
Read More

Study of RTX-240 in Adults with Relapsed/Refractory or Locally Advanced Solid Tumors

Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to learn about the study drug RTX-240. This study is the first time RTX-240 will be used in people. Researchers will be studying the safety and effectiveness of RTX-240 in patients with certain types of cancer. The study will check if RTX-240 causes any changes in your health (or side effects), how…
Read More

A study for patients with Melanoma, Squamous Cell Cancer of the Head and Neck, or Non-Small Cell Lung cancer using study drug MGA271

Condition: Cancer / Head and Neck Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The study involves research about MGA271 in combination with Keytruda. MGA271 targets cancer cells that make a lot of a protein called B7-H3. Another way to say it is that the cells "overexpress" the protein. Very few normal cells express B7-H3. MGA271 is though to work by recognizing cancer…
Read More

Study of RP-3500 in Combination with PARP Inhibitor for Patients with Advanced Cancer

Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
The study is being done to learn how safe and effective the study drug, RP-3500, is when given with either niraparib or olaparib to treat advanced cancer. Niraparib and olaparib belong to a group of drugs called PARP inhibitors. These drugs are designed to block an enzyme called PARP which may stop …
Read More

A Study in Subjects With Advanced Cancer

Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
This research study is studying a drug called AGEN2373 as a possible treatment for advanced cancer. The study drug targets cells that are a part of the body's immune system to block a protein called anti-CD137 agonist antibody. Blocking this protein is believed to improve the ability of your immune system to fight your…
Read More

Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer

Condition: Cancer
Investigator: Bret Taback, MD
Status: Closed
Surgery is the main treatment for many cancer conditions. In many elderly patients, surgery can greatly affect physical condition, and the ability to return to pre-surgery levels of physical functioning. By providing some simple pre-surgical recommendations, it may be possible to improve the rate of recovery from surgery and…
Read More

Study to Evaluate Multiple Treatments for Patients with Newly Diagnosed or Recurrent GBM

Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Currently Recruiting
The purpose of this study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called "study drugs" and are not approved by the Food and…
Read More

Study of Quemliclustat and Chemotherapy vs Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PRISM-1)

Condition: Cancer / Pancreatic Cancer
Investigator: Gulam Manji, MD, PhD
Status: Currently Recruiting
The purpose of this research is to determine the safety and efficacy of investigational study drugquemliclustat (also known as AB680) in combination with chemotherapy gemcitabine and nab-paclitaxel (Gem-NP), compared to a placebo (saline solution not containing treatment drug) in combination with chemotherapy gemcitabine and nab-paclitaxel at treating…
Read More

Study of Chemotherapy Drug, Lomustine, in Addition to Temozolomide in Patients with Glioblastoma (GBM)

Condition: Cancer / Brain Cancer
Investigator: Fabio Iwamoto, MD
Status: Currently Recruiting
The purpose of this study is to compare the usual radiation therapy and usual chemotherapy, temozolomide, to using the usual radiation therapy and usual chemotherapy plus the chemotherapy drug lomustine (Gleostine). Lomustine (Gleostine) is already approved by the FDA for use in brain tumors but it is usually used alone and is not the first-line choice for…
Read More

Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors

Condition: Cancer
Investigator: Catherine Shu, MD
Status: Currently Recruiting
This is a first-in-human clinical research study. This study is sponsored by a biopharmaceutical company named Bicara Therapeutics. The main purpose of this study is to investigate the study drug BCA101 alone and BCA101 in combination with pembrolizumab for its safety, the way the body absorbs, distributes, and gets rid of this study drug, how the study…
Read More

Study of IMC-F106C Alone and in Combination With Checkpoint Inhibitors in Participants with Advanced Cancers

Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
This is a research study to determine how safe and effective a new treatment, called IMC-F106C, is for treating advanced cancers. This study is the first time the study drug is being tested in people. IMC-F106C has been developed to treat cancer by activating the body's own immune system to fight…
Read More

Study of Financial Navigator Addressing Cancer-Related Financial Hardship in Cancer Patients and Their Spouses

Condition: Cancer
Investigator: Dawn Hershman, MD
Status: Closed
Studies have shown that cancer patients and their spouses may be at high risk for financial problems because of the cost of cancer treatment. This study is being done to answer the following question: Can a financial navigation program help patients and their spouses understand and better manage…
Read More

Study of INCB106385 Alone or in Combination with INCMGA00012 in Patients with Advanced Cancer

Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
INCB106385 and INCMGA00012 are drugs being studied by Incyte Corporation for use in the treatment of advanced cancer. These study drugs are known as immune therapies, which are designed to help your immune system become more active and possibly fight your cancer. INCB106385 will be tested either…
Read More

Study of MPT-0118 Alone or in Combination with Keytruda in Patients with Advanced or Metastatic Cancer

Condition: Cancer
Investigator: Shaheer Khan, DO
Status: Closed
The purpose of this study is to see if the investigational drug MPT-0118 is effective in treating people with cancer. This is the first time the study drug, MPT-0118, will be given to humans. MPT-0118 will be given alone (monotherapy) and in combination with Keytruda (pembrolizumab). Pembrolizumab is approved by the FDA to…
Read More

First-in-Human Study of DS-7300a in Subjects with Advanced Cancer

Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
This study will test the investigational drug, DS-7300a, for the first time in humans. DS-7300a is an antibody-drug conjugate (ADC) being developed as an anti-cancer agent. ADCs are made up of a monoclonal antibody chemically linked to a drug. The monoclonal antibody binds to specific proteins or receptors found on certain…
Read More

Study of Eflornithine & Temozolomide in Patients with Glioblastoma Multiforme (GBM)

Condition: Cancer / Brain Cancer
Investigator: Maria Diaz Ordonez, MD
Status: Currently Recruiting
The purpose of this study is to measure how safe eflornithine is in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM) or astrocytoma following radiation therapy. Safety and tolerability will be determined on the basis of physical exams, laboratory tests, and questions about any problems you might experience during…
Read More

Study of HRO761 Alone or in Combination with Tislelizumab or Irinotecan in Patients with Solid Tumors

Condition: Cancer
Investigator: Edmond Chan, MD
Status: Closed
The main purpose of the study is to find the optimal dose of HRO761 alone or in combination with tislelizumab or irinotecan that can be given to people with certain cancer types called MSI high or dMMR. The new drug being tested in the study, HRO761, is an oral drug that is called a targeted medicine: this means that it…
Read More

Study of XL092 Alone or in Combination with Anticancer Therapy in Patients with Unresectable orMetastatic Solid Tumors

Condition: Cancer
Investigator: Karie D. Runcie, MD
Status: Closed
The purpose of this study is to evaluate the efficacy of the study drug, XL092 alone and/or in combination of other study drugs such as with nivolumab, nivolumab plus ipilimumab, or nivolumab/relatlimab fixed-dose combination as a potential anticancer therapy to treat people with locally advanced or metastatic…
Read More

Study of AMG 193 and IDE397 in Patients with Solid Tumors

Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
The purpose of this study is to assess how the study drugs, AMG 193 and IDE397, move throughout the body, how the study drugs work in the body, whether they are safe, and an effective treatment option for people with advanced solid tumors lacking methylthioadenosine phosphorylase (MTAP) in the DNA (genetic material). Lacking MTAP may limit the way in which…
Read More

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the…
Read More

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Cancer

Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of the study is to help the Sponsor understand whether study drugs, AB308 together with zimberelimab (also called AB122) can be safely given to patients with advanced cancers. Zimberelimab (AB122) is an investigational drug that has been shown in animal studies to slow or stop the growth of some…
Read More

Study of New Oral Anti-Cancer Drug (OACD)

Condition: Cancer
Investigator: Dawn Hershman, MD
Status: Closed
In this study, we are evaluating a 30-minute pharmacist-led video consultation to provide education about your new oral anti-cancer drug (OACD) and help identify and manage potential drug-drug interactions alongside your oncologist. Our study aims to evaluate a one-time, 30-minute pharmacist-led video visit among patients…
Read More

Study of PMD-026 in Patients with Metastatic Breast Cancer with Expansion in Metastatic Triple Negative Breast Cancer

Condition: Cancer / Breast Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
This is a first-in-human, phase 1/1b, open-label study of single-agent PMD-026 conducted in participants with metastatic breast cancer. PMD-026 will initially be administered orally on a once-daily schedule. Part 1 of the study will evaluate PMD-026 in participants with metastatic breast cancer…
Read More

Study of PRT3789 in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
The purpose of this research study is to test the safety of an investigational drug, PRT3789, at different dose levels to find out what effects, good and/or bad, PRT3789 has on Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation. Mutations are changes or alterations in the DNA (genetic material) of your cells. A SMARCA4 mutation has been linked to…
Read More

Study of BA3011 in Subjects with Advanced Solid Tumors

Condition: Cancer
Investigator: Prabhjot Mundi, MD
Status: Closed
The purpose of this study is to test the safety of different doses of BA3011 and to find out what effects, good and/or bad, that it has on advanced solid tumor cancers that have tested positive for the AXL protein. AXL is a protein found on certain types of cancer cells. This research study will…
Read More

Study of Focused Ultrasound (FUS) with DEFINITY Microbubbles in Children and Young Adults with Progressive Diffuse Midline Glioma (DMG)

Condition: Cancer / Brain Cancer
Investigator: James Hinkley Garvin Jr, MD
Status: Currently Recruiting
Children and young adults with diffuse midline glioma will be treated with Focused Ultrasound (FUS) with DEFINITY microbubbles and neuro-navigator-controlled sonication. The overall goal of this study is to see if the study treatment plan will improve the outcome of participants with diffuse midline glioma, for which no known cure exists, and determine…
Read More

Study of Lutathera in Patients with Glioblastoma (GB)

Condition: Cancer / Brain Cancer
Investigator: Mikhail Doubrovin, MD
Status: Currently Recruiting
The purpose of the study is to evaluate the safety of Lutathera alone in patients with recurrent glioblastoma and the combination of Lutathera with radiotherapy with temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GB) and to establish the appropriate dose of this combination. Lutathera is a radioligand therapy, which is a targeted…
Read More

Study of ONC201 After Radiation in Patients with Glioma

Condition: Cancer / Brain Cancer
Investigator: Aya Haggiagi, MD
Status: Currently Recruiting
The purpose of this study is to see if ONC201 is effective in treating participants with glioma when given following radiation therapy, how safe and tolerable ONC201 as compared to using placebo (a capsule that looks like ONC201 but does not contain any active drug), and to see how well ONC201 can improve quality of life and brain functioning in patients…
Read More

Study of XmAb819 in Patients with Clear Cell Renal Cell Carcinoma

Condition: Cancer / Kidney Cancer
Investigator: Karie D. Runcie, MD
Status: Currently Recruiting
The purpose of this study is to assess whether an investigational drug called XmAb819 has any effects on Clear Cell Renal Cell Carcinoma, to determine if it is safe and well tolerated, and to determine the dosing schedule. The investigational drug will be given by intravenous (IV into the vein) infusion over a 2-hour period. This study will also see how the…
Read More

A Study of BMS-986340 Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Condition: Cancer
Investigator: Ryan Moy, MD
Status: Currently Recruiting
The main purpose of this study is to test the safety of the investigational drug, BMS-986340, administered alone and in combination with nivolumab. This study will investigate how patients with selected advanced solid tumors tolerate these drugs to identify the highest tolerable dose or the most suitable dose, explore any changes in your tumor, and your…
Read More

Study of BT7480 in Patients with Advanced Cancer

Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to evaluate whether the investigational drug, BT7480, will be a safe and effective anticancer therapy. This is the first time BT7480 will be given to humans. BT7480 is designed to recognize and attach itself to both the Nectin-4 protein found on the surface of some cancer…
Read More

Study of Imprime PGG and Pembrolizumab (Keytruda) in Patients with Metastatic Breast Cancer (mBCA)

Condition: Cancer / Breast Cancer
Investigator: Julia McGuinness, MD
Status: Closed
The purpose of this study is to find out, good and/or bad, the effects of the investigational drug, Imprime PGG, when given together with pembrolizumab (also known as Keytruda, a type of checkpoint inhibitor) in the treatment of your type of cancer. Checkpoint inhibitors are a type of immunotherapy that block immune checkpoint…
Read More

Study of PF-07263689 Alone or in Combination with Sasanlimab for Patients with Advanced Cancer

Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to learn about the safety and anti-cancer effectiveness of the investigational study drug called PF-07263689, as a single agent and in combination with sasanlimab, another investigational study drug that is an anti-PD 1 antibody. PF 07263689 is a weakened, live virus form of the pox-type virus (…
Read More

Study of RP-1664 in Patients with Solid Tumors

Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
The purpose of this study is to learn how well RP-1664 alone works to treat advanced solid tumor. RP-1664 has not been approved by the Food and Drug Administration (FDA). RP-1664 has not been given to humans prior to this study. Cancers include: bladder cancer, breast …
Read More

Study of CC-94676 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Condition: Cancer / Prostate Cancer
Investigator: Karie D. Runcie, MD
Status: Closed
You are being asked to take part in this study because you have been diagnosed with advanced prostate cancer and the standard drugs to treat your disease (metastatic castration-resistant prostate cancer mCRPC) are no longer effective or no effective treatment is known for your type of…
Read More

Study of CS5001 in Patients with Advanced Solid Tumors

Condition: Cancer
Investigator: Hua-Jay Cherng, MD
Status: Closed
This is a study of the experimental drug CS5001 developed by CStone pharmaceutical, in patients with advanced hematological and solid tumors. CS5001 will target certain receptors that are in high levels on cancer cells. This study will look at the anti-tumor activity of CS5001. CS5001 is not approved by any regulatory agency…
Read More

Study of Ulixertinib (BVD-523) for Patients with Advanced Cancer that Show Genetic Alterations

Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to assess the safety and tolerability of an experimental study drug called ulixertinib (BVD-523) in the treatment of advanced cancer that shows certain genetic alterations (changes in the DNA) called MEK or atypical BRAF alterations and is getting worse. Experimental means that ulixertinib has not…
Read More

Study of GEN-011 for Adult Patients with Advanced Cancer

Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
GEN-011 is an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune cells. First, the cancer proteins that are already recognized by the patient's T cells are found. Then…
Read More

Study of a Neoantigen Cancer Vaccine in Patients with Advanced Solid Tumors (Bladder, Colon, Stomach, Lung, Esophageal, or Rectal Cancer)

Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this research study is to learn more about an experimental personalized vaccine that has two components called GRT-C901 and GRT-R902. We will learn more about the effects of this vaccine on your cancer when used together with approved medications that activate the immune system, nivolumab (Opdivo) as well as…
Read More

TCR-engineered T Cells in Solid Tumors With Focus on Non-small Cell Lung Cancer (NSCLC) and Head and Neck Squamous Cell Carcinoma (HNSCC)

Condition: Cancer
Investigator: Ran Reshef, MD
Status: Closed
The goal of the study is to learn if it is safe to give genetically changed T cells (IMA201) in combination with standard of care chemotherapy (fludarabine and cyclophosphamide) and IL-2 (aldesleukin) to patients with solid tumors that have grown or returned after being treated. Researchers also want to learn about possible side effects of IMA201 and if the…
Read More

A study for patients with incurable cancers using study drug CPI-444

Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
This study is for patients with incurable cancers such as, metastatic non-small cell lung cancer, melanoma, renal cell carcinoma, triple negative breast cancer, colorectal cancer, head and neck cancer,…
Read More

A study for patients with advanced cancers using study drugs PF-04518600 and PF-05082566

Condition: Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this research is to learn about the effects of 2 new investigational drugs, PF-04518600 and PF-05082566. PF-04518600 and PF-05082566 are antibodies (a type of protein) which have been shown to stimulate the immune system. Research has shown that an immune response like this can work against tumor cells to slow tumor growth by causing tumor…
Read More

Study of Drug Combination in Subjects with Triple Negative Breast Cancer or Colorectal Cancer with Liver Metastases

Condition: Cancer
Investigator: Kevin Kalinsky, MD, MS
Status: Closed
The purpose of this study is to find out whether the drug talimogene laherparepvec in combination with another drug atezolizumab is safe for people with triple negative breast cancer or colorectal cancer with liver metastases and whether this drug combination causes any side effects.
Read More

A study for patients with advanced cancers using study drugs MEDI0680 and MEDI4736

Condition: Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is for individuals with advanced cancers. Only patients with non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), colorectal cancer (CRC), bladder cancer, ovarian …
Read More

Study of Symptom Monitoring using Young, Empowered & Strong (YES) Web Portal for Breast Cancer Survivors

Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
The Young, Empowered & Strong (YES) study is opened to women who were diagnosed with breast cancer between the ages of 15 and 39 years. Women will need to be within 3 years of the end of early active treatment (e.g. surgery, chemotherapy not including HER2-directed therapy, radiation), and have no know evidence of breast…
Read More

Study of Abiraterone Acetate, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to find out whether delivering SBRT to the prostate, combined with the study drug atezolizumab, is a safe and effective treatment when given in combination with abiraterone, prednisone, and Lupron (the standard treatment for this disease). In addition, the researchers want to find out whether the study treatment works better…
Read More

Study of Adagrasib Alone or in Combination with Nivolumab Non-Small Cell Lung Cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
The purpose of this study is to assess the benefits and risks of the study drug, adagrasib, when given either by itself or with another drug, nivolumab, to participants with non-small cell lung cancer and a specific cancer mutation, called KRAS G12C, and whether the study drug or the combination…
Read More

Study of VTP-850 in Male Patients with Prostate Cancer Whose Prostate-Specific Antigen (PSA) Levels Have Risen

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to determine how safe the study drug, VTP-850, is in people with prostate cancer who have had initial treatment but whose prostate-specific antigen (PSA) levels have started to rise again. This study also aims to find the appropriate dose regimen of VTP-850 that can be given safely to people with…
Read More

Study of RMC-6291 in Patients with Advanced Solid Tumors

Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
The purpose of this study is to test a new drug called RMC-6291, to evaluate its safety at different doses, and to find out how the body processes it. RMC-6291 is a new experimental drug, which means that it is not approved by the US Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC-6291 will be tested…
Read More

Study of Patritumab Deruxtecan in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to determine the combination dose of patritumab deruxtecan and osimertinib that can be given to patients safely and to understand how well patritumab deruxtecan alone or in combination with osimertinib works to treat lung cancer. Osimertinib is an EGFR TKI therapy that targets EGFR mutations.…
Read More

Study of Drug in Patients with Early Stage Non-Small Cell Lung Cancer

Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body's immune system to attack any …
Read More

BWEL: Breast Cancer Weight Loss Trial

Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast…
Read More

Study of Breast Cancer and Colorectal Cancer Patients with Tingling, Pain, or Numbness after Chemotherapy

Condition: Cancer
Investigator: Dawn Hershman, MD
Status: Closed
This study examines the effects of the study drug, topical menthol, on neuropathic symptoms, such as a tingling, pain or numbness caused by nerve damage, following chemotherapy among breast and colorectal cancer patients.
Read More

Identifying tumor neoantigens during immune checkpoint blockade in patients with non-small cell lung cancer

Condition: Cancer / Lung Cancer
Investigator: Adrian Sacher
Status: Closed
This study is for adults who have non-small cell lung cancer and have had surgery to remove their lung tumor. People who have lung cancer and undergo surgery still have a significant risk of their cancer returning outside of the lung. The purpose of this study is to…
Read More

A study for women with ovarian cancer using study drug farletuzumab

Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
This study will only include women who have platinum sensitive relapsed epithelial ovarian cancer meaning your ovarian cancer did not return for at least 6 months after your first treatment with chemotherapy containing platinum (carboplatin or cisplatin). This research is being done to find out…
Read More

Study of SL-172154 in Combination with PLD or MIRV in Patients with Ovarian Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Closed
The purpose of this research study is to test the safety and determine the highest tolerable dose of SL-172154 (study drug) that can be given with Pegylated Liposomal Doxorubicin (PLD) or Mirvetuximab Soravtansine (MIRV). Another purpose of this study is to understand if SL-127154 and PLD or MIRV is effective in managing ovarian …
Read More

Study of Gavo-Cel Alone or in Combination with Nivolumab or Ipilimumab in Patients with Advanced Cancer

Condition: Cancer
Investigator: Ran Reshef, MD
Status: Closed
This study involves research of an investigational therapy called gavo-cel. The purpose of this study is to test the safety and the efficacy (how well the drug works to treat your cancer) of gavo-cel, possibly in combination with one or two additional FDA-approved drugs called nivolumab and ipilimumab, to find out what effects…
Read More

Study of BGB-16673 in Patients with Leukemia or Lymphoma

Condition: Cancer
Investigator: Nicole Lamanna, MD
Status: Currently Recruiting
The purpose of this study is to look at the safety and tolerability of the study drug, BGB-16673. Another purpose is to determine the range of BGB-16673 doses that can safely be used. BGB-16673 is an experimental drug. This means that it has not been approved for treatment by the US, the Food and Drug Administration (FDA). This research study is the first…
Read More

Cooling and Compression to Prevent Nerve Damage During Chemotherapy

Condition: Cancer
Investigator: Melissa Accordino, MD
Status: Currently Recruiting
The purpose of this study is to learn which of the following 3 study approaches is the most helpful to prevent peripheral neuropathy caused by taxane chemotherapy. These approaches will use a study device, called the Paxman Limb Cryocompression System, made of wraps that cool and/or compress your arms and legs. The study will test which of the following…
Read More

Study of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS)

Condition: Cancer
Investigator: Divaya Bhutani, MD
Status: Currently Recruiting
The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with Monoclonal Gammopathy of Renal Significance (MGRS). Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat Monoclonal Gammopathy of Renal…
Read More

Tissue Repository For The Collection of Hematologic Samples

Condition: Cancer
Investigator: Suzanne Lentzsch, MD
Status: Currently Recruiting
Subjects are being asked to volunteer to allow excess specimen (blood, bone marrow samples, samples of pleural and pericardial effusions, ascites, tissue, and bone samples) removed from patients with and who are undergoing procedures for hematological and non-hematological disorders for storage and future use. These samples will be placed in the human…
Read More

Study of NDI-101150 Alone or in Combination with Pembrolizumab in Patients with Solid Tumors

Condition: Cancer
Investigator: Ryan Moy, MD
Status: Closed
The purpose of this study is to find out if a new investigational drug NDI-101150 is safe when given alone and in combination with pembrolizumab, and to look at the pharmacokinetics (PK, to measure how your body takes up, breaks down, and clears NDI-101150) and the antitumor activity (to measure how NDI-101150 works in your tumors). Investigational means…
Read More

Study of BAY 1895344 in Combination with Chemotherapy for Patients with Advanced Cancer

Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
This study is being done to answer the following question: What is the highest dose of BAY 1895344 that can be given safely in combination with cisplatin and gemcitabine in patients with advanced solid tumors, including urothelial carcinoma? We are doing this study because we want to find out if this approach is better or worse than the usual approach for…
Read More

Study of ADXS-504 in Patients with Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
This study aims to investigate ADXS-504 as a possible treatment for biochemically recurrent prostate cancer. ADXS-504 is a type of cancer treatment that is designed to stimulate your immune system to attack prostate cancer cells. ADXS-504 is made of bacteria that…
Read More

Study of Atezolizumab and Tiragolumab Alone or in Combination with Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to assess the effects, good or bad, of atezolizumab and tiragolumab given with or without chemotherapy (in this study, chemotherapy will be a combination of either paclitaxel with carboplatin, pemetrexed with carboplatin or cisplatin, or gemcitabine with carboplatin or cisplatin) on patients who are able to have surgery to…
Read More

Study of Lutetium-177 PSMA I&T in Patients with Castration-Resistant Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
This study is being done to learn if the study drug called Lutetium-177 PSMA I&T is safe and effective in patients with castration-resistant metastatic prostate cancer. The study drug contains radioactive Lutetium-177, which is targeted to treat certain prostate cancers cells that have a…
Read More

Study of IV Contrast on Patients Going Through Image Guided Radiation Therapy (IGRT) for Abdominal and Pelvic Cancer

Condition: Cancer
Investigator: David Horowitz, MD
Status: Closed
The purpose of this study is to find out if giving intravenous (IV) contrast (a liquid that helps with the visibility of organs and blood vessels that is given through the vein with the use of a hollow needle) during a Cone Beam Computed Tomography (CBCT- a type of computerized X-ray) can help people who have image-guided radiation therapy (IGRT) for the…
Read More

Study of BAY 1895344 in Combination with Chemotherapy for Patients with Metastatic Gastrointestinal Cancer

Condition: Cancer
Investigator: Ryan Moy, MD
Status: Closed
This study is being done to answer the following question: What is the highest dose of BAY 1895344 and FOLFIRI chemotherapy (irinotecan, 5-fluorouracil, which is also known as 5-FU, and leucovorin) in combination that can be safely and tolerably taken in patients with advanced gastrointestinal cancer? This is the first time…
Read More

Study of Drug (MK-2118) in Patients with Solid Tumors or Lymphomas

Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to: test the safety of the study drug and see how your body handles it, find the highest dose of the study drug that can be given alone or in combination with embrolizumab (MK-3475) with the least risk of serious side effects. The study drug is called MK-2118. Solid tumor or lymphoma cancers…
Read More

Study of Upifitamab Rilsodotin (XMT-1536) in Patients with Recurrent Ovarian Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
XMT-1536 (upifitamab rilsodotin) is a targeted therapy, which means that it is directed specifically at a tumor. It is a type of antibody-drug conjugate; this means it has 2 parts that are joined together into one drug. The first part is an antibody that binds to NaPi2b (sodium-dependent phosphate transporter), a protein on the surface of the cells of your…
Read More

Study of Osimertinib (TAGRISSOTM) in Patients with Non-Small Cell Lung Cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study to learn more about whether the study drug osimertinib (TAGRISSOTM) is more effective than placebo in participants with epidermal growth factor receptor (EGFR) mutated stage IA2 or IA3 Non-Small Cell Lung Cancer (NSCLC) after complete surgical removal of the tumor. Stages IA2 and IA3 refer to tumor…
Read More

Study of Apalutamide Alone or in Combination with ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Condition: Cancer / Prostate Cancer
Investigator: Karie D. Runcie, MD
Status: Closed
The purpose of this study is to help researchers understand more about the possible effectiveness and safety of apalutamide when given to patients with or without intermittent Androgen Deprivation Therapy (ADT) to treat metastatic Castration-Sensitive Prostate Cancer (mCSPC). Apalutamide is a type of drug that blocks the…
Read More

Study of Radiation Therapy Alone or in Combination With Olaparib for Patients with Inflammatory Breast Cancer (IBC)

Condition: Cancer / Breast Cancer
Investigator: Eileen Connolly, MD, PhD
Status: Closed
This study is being done to answer the following question: Can we lower the chance of your cancer returning by adding the drug olaparib to the usual radiation therapy for your cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach…
Read More

Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to determine the safety and effectiveness of two drugs, either rituximab or tocilizumab, in patients who develop side effects while on treatment with immunotherapy requiring prolonged steroids. Immune-related side effects are caused by activation of the immune system from treatment with immunotherapy. Both rituximab and…
Read More

Study of Savolitinib in Combination with Osimertinib vs. Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to learn more about an investigational drug called savolitinib in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC) compared to platinum-based doublet chemotherapy (a standard of care treatment). Participants will be randomly assigned to one of two study groups at…
Read More

Decreasing Chemotherapy for HER2 Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Condition: Cancer / Breast Cancer
Investigator: Julia McGuinness, MD
Status: Closed
This study is being done to answer the following question: Can participants with HER2-positive breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after 12 weeks of chemotherapy and two HER-targeted therapies eliminate further chemotherapy after…
Read More

Study of Abemaciclib in Combination with Letrozole in Women with Endometrial Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
The purpose of this study is to find out of the combination of the drugs abemaciclib and letrozole is better or worse than usual approach for your type of cancer. The usual approach is defined as care most people get for endometrial cancer. People who are not in a study are usually treated with…
Read More

Study of MORAb-202 in Women with Ovarian, Fallopian, or Primary Peritoneal Cancer (PPC)

Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Closed
By doing this study, researchers hope to learn more about the efficacy (how well the drug works) and safety (the drugs side effects) of MORAb-202 (farletuzumab ecteribulin) compared to approved chemotherapy medications in patients with platinum-resistant ovarian cancer. The study will evaluate two doses of MORAb-202. MORAb-202…
Read More

Molecular Analysis for Therapy Choice (MATCH)

Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas (including breast cancer, esophageal cancer, lung cancer, sarcomas - bone and soft…
Read More

Study of HPN424 in Patients With Advanced Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to test the effectiveness and safety of an experimental drug known as HPN424 (also known as study drug) in patients with advanced prostate cancer. This drug has been tested in animals but not yet in people. This study tests different doses of HPN424. We want to find out how good the drug is at…
Read More

A Study of LGK974 in Patients With Cancer

Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
This primary purpose of this study is to find the recommended dose of LGK974 and PDR001 that can be safely given to adult patients who have advanced metastatic pancreatic cancer, or triple negative breast (TNB) cancer, or melanoma, lung squamous cell cancer,…
Read More

Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer

Condition: Cancer / Breast Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
The purpose of this study is to compare any good and bad effects of using olaparib and atezolizumab in combination compared to olaparib alone. The use of olaparib alone or in combination with atezolizumab could shrink your cancer but could also cause side effects. This study will allow the researchers to know whether the…
Read More

The ABC Trial: Study of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer

Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever,…
Read More

Study of Study Drug MGD009 in Patients with Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Charles Drake, MD
Status: Closed
We are doing this study to test a drug called MGD009. MGD009 is like an antibody, which is a protein in your blood that helps get rid of germs in your body. MGD009 is made to attach to cancer cells and to T-cells, which are a part of your immune system. Certain T cells have the ability to kill other cells, including…
Read More

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201)

Condition: Cancer / Bladder Cancer
Investigator: Mark Stein, MD
Status: Closed
This clinical trial is for patients who have cancer of the urinary system (urothelial cancer, including cancer of the bladder, renal pelvis, ureter or urethra) that has spread to nearby tissues or to other areas of the body who have already been treated with a kind…
Read More

A study for patients with advanced cancers using study drug PEN-221

Condition: Cancer
Investigator: Antonio Fojo, MD, PhD
Status: Closed
This study is for patients with advanced cancers such as gastroenteropancreatic or lung or thymus or other neuroendocrine tumors or small cell lung cancer or large cell neuroendocrine carcinoma of the lung. This research study tests whether an experimental drug called PEN-221 may help people…
Read More

18F-DCFPyL PET/CT in Men with Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to see if 18FDCFPyL (PyL) PET/CT scans are able to find prostate cancer tumors. PyL is a radioactive drug (tracer) that targets prostate specific membrane antigen (PSMA). Because PSMA is a protein found mostly on the surface of prostate cancer cells, we are testing to…
Read More

Study of Telaglenastat in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to determine the amount (dose) of telaglenastat that is safe and tolerable when given together with the recommended treatment regimen of pembrolizumab, carboplatin, and pemetrexed and to determine if the combination of standard drugs with telaglenastat is more active against non-small cell lung cancer…
Read More

Study of Radiation Therapy in Female Patients with Breast Cancer who Have Undergone Surgery

Condition: Cancer / Breast Cancer
Investigator: Eileen Connolly, MD, PhD
Status: Closed
The main purpose of this clinical trial is to study women like you who have cancer cells in the lymph nodes at the time that the breast cancer is diagnosed and have chemotherapy before surgery that clears the cancer cells from the lymph nodes. This study asks 1) if…
Read More

A Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients with Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
This research study is investigating a new treatment for cancer that uses your immune system (a type of white blood cell called T cells or T lymphocytes) to try to attack your cancerous cells. T cells fight infections, and may attack cancer cells, in some cases.…
Read More

A study for patients with liver cancer using study drug RO7070179

Condition: Cancer / Liver Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to assess the safety, tolerability, and effectiveness of RO7070179 given to patients with Hepatocellular Carcinoma (HCC), a primary type of liver cancer, with normal to moderately impaired liver function. RO7070179 is given intravenously to study its effects in the treatment of liver…
Read More

Study of Ramucirumab Plus Pembrolizumab vs. Standard of Care in Patients with Non-Small Cell Lung Cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Stephanie Smith-Marrone, MD
Status: Closed
The purpose of this study is to compare the drugs ramucirumab and pembrolizumab to standard-of-care treatment in patients whose lung cancer has progressed on immunotherapy. The study doctors hope to learn if the drug combination will help patients with stage IV or recurrent non-small cell lung cancer…
Read More

TCR-engineered T Cells in Solid Tumors (ACTengine)

Condition: Cancer
Investigator: Ran Reshef, MD
Status: Closed
The goal of the study is to learn if it is safe to give genetically changed T cells in combination with standard-of-care chemotherapy (fludarabine and cyclophosphamide) and IL-2 (aldesleukin) to patients with solid tumors that have grown or returned after being treated. Researchers also want to learn about possible side effects of the study drug and if the…
Read More

Study of Niraparib in Patients Who Have Been Previously Treated for Breast Cancer

Condition: Cancer / Breast Cancer
Investigator: Julia McGuinness, MD
Status: Closed
The purpose of this study is to evaluate if the study drug, niraparib will help patients delay or prevent their breast cancer from returning. This study will compare niraparib to placebo in study participants who have been treated for breast cancer and were then found to have breast…
Read More

Study of RP-6306 in Combination with Gemcitabine (Chemotherapy) for Patients with Advanced Solid Tumors

Condition: Cancer
Investigator: Ryan Moy, MD
Status: Closed
The purpose of this study is to learn how well RP-6306 (study drug) in combination with gemcitabine works to treat certain types of cancer. RP-6306 is a drug that is designed to stop certain cancer cells from growing by blocking a protein called PKMYT1. It is an investigational drug, which means…
Read More

Study of JNJ-93841937 Participants with Advanced Non-Small Cell Lung Cancer

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to see if lazertinib and JNJ-61186372 are safe and useful for treating patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC) as well as looking at the effects that lazertinib and JNJ-61186372 have when taken together. Lazertinib is…
Read More

Study of Durvalumab + Tremelimumab in Non-Small Cell Lung Cancer Patients After Adjuvant Treatment

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this research study is to see how effective durvalumab andtremelimumab is in patients with early stage non-small cell lung cancer (NSCLC). A a special blood test will be done to see if subjects have circulating tumor DNA (ctDNA) in their blood. ctDNA are pieces of genetic material shed from the tumor cells that…
Read More

Testing different doses of Exemestane in women with early breast cancer (MDA2014-04-01)

Condition: Cancer / Breast Cancer
Investigator: Katherine Crew, MD
Status: Closed
This randomized phase IIb trial studies how well alternative dosing of exemestane before surgery works in treating postmenopausal patients with stage 0-II estrogen positive breast cancer. Chemoprevention is the use of drugs to keep breast cancer from forming or coming back. The use of exemestane…
Read More

Study of Pembrolizumab Plus Chemotherapy versus Chemotherapy Plus Placebo in Patients with Cervical Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
Test the safety and effectiveness of the research study drug, pembrolizumab (MK-3475) in combination with chemotherapy, compared to chemotherapy plus placebo (a look-alike drug with no active ingredients) in women with persistent, recurrent, or metastatic cervical cancer. To test if adding pembrolizumab (MK-3475) to standard…
Read More

A study for patients with biliary or gallbladder cancer using study drug DKN-01

Condition: Cancer / Liver Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
This research study is being done to see how an investigational drug called DKN-01 combined with standard cancer drugs (gemcitabine and cisplatin) works in people with biliary or gallbladder cancer. DKN-01 is an antibody that blocks the function of another protein in the body called dickkopf-1 (…
Read More

Study Evaluating Everolimus with Endocrine Therapy in Breast Cancer Patients

Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
The purpose of this study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without the subjects cancer returning. The current standard treatment after chemotherapy is hormone treatment alone. Everolimus is a drug currently approved for the treatment of patients with…
Read More

nab-Rapamycin Treatment for BCG Refractory Bladder Cancer

Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The study is part of a research program to assess the efficacy of the drug nab-rapamycin, a biologic mTOR inhibitor. The purpose of the study is to assess the response rate, as well as, the safety of administering nab-rapamycin in combination with gemcitabine directly into the bladder in an effort to treat bladder cancer. The…
Read More

Diffuse Optical Tomography in Prostate Cancer Detection and Risk Stratification - A Pilot Study

Condition: Cancer / Prostate Cancer
Investigator: Emerson Lim, MD
Status: Closed
You are being asked to join this study because you have either been diagnosed with prostate cancer and will be having surgery to remove your prostate or you will be having a prostate biopsy to look for prostate cancer. This study is looking to see if a new imaging device, diffuse optical…
Read More

A study for men with non-metastatic prostate cancer using study drugs enzalutamide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide

Condition: Cancer / Prostate Cancer
Investigator: Richard Carvajal, MD
Status: Closed
This study will enroll participants with prostate cancer that were treated by removing the prostate or by giving radiation (or both), but whose blood prostate specific antigen (PSA) level is going up. PSA is produced by the prostate and other tissues, and when it goes up, it means that the prostate …
Read More

Study of Drug in Combination with Traditional Chemotherapy for Patients with Stage IV Small-Cell Lung Cancer (SCLC)

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This trial will look at how the study drug will work in combination with traditional chemotherapy at treating extensive-stage small cell lung cancer in the first-line setting. The study will also determine if these drugs cause any side effects compared to traditional chemotherapy alone. The study drug is Durvalumab by itself…
Read More

Study for patients with melanoma, non-small cell lung cancer (NSCLC) or squamous cell cancer of the head and neck (SCCHN) using drug B7-H3

Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Richard Carvajal, MD
Status: Closed
This study is for patients with melanoma, non-small cell lung cancer (NSCLC), or squamous cell cancer of the head and neck (SCCHN) that has a protein called B7-H3 on the tumor cells or blood vessels in thetumor. The purpose of this study is to test the safety, tolerability, and most effective…
Read More

Study of Pembrolizumab (MK-3475) in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Condition: Cancer / Prostate Cancer
Investigator: Charles Drake, MD
Status: Closed
The purpose of this clinical trial to find out if the investigational medication pembrolizumab in combination with enzalutamide + Androgen Deprivation Therapy (ADT) is safe and works to slow down or stop the growth of metastatic prostate cancer compared to enzalutamide + ADT alone. Pembrolizumab is a type of immunotherapy,…
Read More

Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer

Condition: Cancer / Thyroid Cancer
Investigator: Antonio Fojo, MD, PhD
Status: Closed
This is a study designed for patients with medullary thyroid cancer. Treatment will consist of a drug called Ponatinib. Ponatinib is an investigational agent that blocks abnormal cancer proteins and therefore harms cancer cells. It was recently approved by the Food…
Read More

A study for women with ovarian cancer using study drug lurbinectedin

Condition: Cancer / Gynecologic Cancer
Investigator: Ana Tergas, MD
Status: Closed
The main aim of this clinical trial is to know the effects (good or bad) that study drug lurbinectedin (PM01183), has on women with ovarian cancer. Lurbinectedin (PM01183), is an investigational drug. This means that the drug has not been approved by the Food and Drug Administration (FDA) for medical use in patients, but has…
Read More

Study of Breast Cancer in Black Women

Condition: Cancer / Breast Cancer
Investigator: Lauren Houghton, PhD
Status: Closed
We are conducting a series of focus group sessions to investigate the attitudes and opinions of young Black women regarding breast cancer, breast cancer risk, and biomarker-based screening to inform current breast cancer screening guidelines.
Read More

Study of ASKG915 in Patients with Advanced Solid Tumors

Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to test the safety and effectiveness of ASKG915 at different dose levels to find out what effects, good or bad, this study drug has on you and your cancer. ASKG915 is an experimental treatment that is being developed for treating people with advanced solid tumors. Experimental means the study drug…
Read More

Study of Combining Osimertinib with and without Ramucirumab in Non-Small Cell Lung Cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to compare the usual treatment for Non-Small Cell Lung Cancer (osimertinib) to a combination therapy (osimertinib plus ramucirumab). The combination therapy arm is testing if ramucirumab can help osimertinib control the abnormal EGRG protein for a longer time and keep the disease inactive longer.…
Read More

Study of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple-Negative Breast Cancer

Condition: Cancer / Breast Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
This study is being done to answer the following question: How does the combination of copanlisib and eribulin compare to eribulin alone to lengthen the time you can live with your metastatic triple-negative breast cancer without your cancer getting worse? We are doing this study because we want…
Read More

Study of XmAb20717 in Patients with Gynecological Cancer (Cervical, Ovarian, or Endometrial)

Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Closed
The purpose of this study is to assess whether an investigational drug, called XmAb20717, has any effects on your cancer, and to determine if it is safe and well tolerated. XmAb20717 is a type of drug that can attach to 2 different proteins, call a bispecific antibody. These antibodies are designed to attach to a T-cell, a…
Read More

Study of Pembrolizumab Alone or in Combination with Chemotherapy in Older Patients with Non-Small Cell Lung Cancer

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This trial studies the side effects of pembrolizumab with or without chemotherapy in treating patients with non-small cell lung cancer that has come back and has spread to other places in the body. Pembrolizumab is an immunotherapy that may help the body's immune system attack the cancer, and may…
Read More

Study in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) whose Disease has Gotten Worse After Osermitinib Treatment

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to gain a better understanding of why some patients with non-small cell lung cancer and an epidermal growth factor receptor (EGFR-sensitizing mutation, fail first-line treatment with the drug osermitinib. Additionally, the purpose is to explore different drug therapies for patients whose…
Read More

Study of Improving Patient-Centered Communication in Patients with Breast Cancer

Condition: Cancer / Breast Cancer
Investigator: Bret Taback, MD
Status: Closed
This study is being done to answer the following question: How can we best help patients and their clinicians make decisions about breast cancer treatment (surgery and other treatments, like radiation and chemotherapy)? We are doing this study because we want to better understand how to support patients in making decisions…
Read More

Study of Study Drug JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to see if the study drug, JNJ-61186372, is safe and useful for treating patients with advanced, metastatic, non-small cell lung cancer (NSCLC). There are 2 parts of this study. The first part is to determine the dose of JNJ-61186372 that is safe to give to patients with non-small cell lung…
Read More

Study of Capmatinib for Patients with Non-Small Cell Lung Cancer (NSCLC)

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this research study is to find out if a drug called capmatinib is safe and effective (can help people) in people who have non-small cell lung cancer (NSCLC) who are also eligible for surgery. Capmatinib is an oral drug that targets particular processes, which may not be working properly in the…
Read More

Study of androgen deprivation therapy followed by chemoimmunotherpy for newly metastatic hormone-sensitive prostate cancer (mHSPC)

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to determine if the addition of immunotherapy to the current standard of care for metastatic prostate cancer, chemotherapy, and hormonal therapy, is safe and improves your response to therapy. People who usually have metastatic prostate cancer to their bones and…
Read More

First-in-Human Study of PF-07225570 Alone or in Combination with Sasanlimab for Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)

Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This is a Phase 1 study (the first time this treatment is being tested in humans) of an anti-cancer study drug called as PF-07225570. This study drug works on stimulating certain cells in the immune system. The study will test different doses that increase (dose escalation) and at the appropriate time, additional patients will…
Read More

Study of efficacy of ribociclib plus fulvestrant in patients with metastatic breast cancer

Condition: Cancer / Breast Cancer
Investigator: Melissa Accordino, MD
Status: Closed
The purpose of this study is to determine whether there is clinical benefit to continue therapy beyondprogression for metastatic or unresectable breast cancer. The treatment that is being investigated in this clinical trial, ribociclib (LEE011), is part of a family of oral medications (pills) that are called Cyclin Dependent…
Read More

A Study of BA3021 in Patients with Advanced Solid Tumors (Lung Cancer, Triple Negative Breast Cancer, or Soft Tissue Sarcoma)

Condition: Cancer / Solid Tumors
Investigator: Brian Henick, MD
Status: Closed
BioAtla (the sponsor of the clinical trial) is studying BA3021 as a potential treatment for varieties of cancers including but not limited to lung, triple negative breast cancer and soft tissue sarcoma. The purpose of this research study is to test the safety of different doses of BA3021 and to…
Read More

Study of Immunotherapy with Nivolumab or BMS-986253 Added to Degarelix in Patients with Prostate Cancer (MAGIC-8)

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
This study is for patients with prostate cancer and that require treatment because their disease is now growing. The purpose of this study is to see whether immunotherapy with nivolumab added to degarelix or nivolumab and BMS-986253 added to degarelix is safe and can decrease the chance that the cancer…
Read More

Cabozantinib With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Kidney Cancer (COSMIC-313)

Condition: Cancer / Kidney Cancer
Investigator: Mark Stein, MD
Status: Closed
This study will test whether cabozantinib in combination with nivolumab plus ipilimumab is more effective (works better) than nivolumab plus ipilimumab alone in treating patients with advanced kidney cancer who have not received prior treatment for their cancer. This study will also examine how…
Read More

Study of Platinum and Etoposide vs. Temozolomide and Capecitabine in Patients With Advanced Gastroenteropancreatic Neuroendocrine Cancer

Condition: Cancer
Investigator: Antonio Fojo, MD, PhD
Status: Closed
The purpose of this study is to compare the effects, both good and bad, of the study drugs temozolomide and capecitabine to the usual chemotherapy treatment for this disease of cisplatin or carboplatin (referred to as platinum therapy) and etoposide. Usually the first treatment given for this cancer is platinum therapy and…
Read More

A study for patients with advanced cancers using study drug JNJ-61610588

Condition: Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to see if JNJ-61610588 is safe and useful for treating patients with cancer. Another purpose is to find out how long JNJ-61610588 stays in and acts on your body and how your body responds to it. The first part will find the dose of JNJ-61610588 that would be best to give to …
Read More

A study for patients with LIV-1-positive metastatic breast cancer using study drug SGN-LIV1A

Condition: Cancer / Breast Cancer
Investigator: Kevin Kalinsky, MD, MS
Status: Closed
The purpose of this study is to find out what side effects (unwanted effects) are caused in patients with breast cancer who are given SGN-LIV1A (single therapy). This study will also look at other effects of SGN-LIV1A, including its effect on this type of cancer. This study is also being done to…
Read More

A study for patients with advanced bladder cancer using study drug MOXR0916

Condition: Cancer
Investigator: Charles Drake, MD
Status: Closed
The purpose of this study is to find out what effects, whether good or bad, that the combination of MOXR0916 plus atezolizumab has on you and your bladder cancer (locally advanced or metastatic urothelial cancer). Atezolizumab is approved in the United States for subjects with bladder…
Read More

Assessing Access to and Delivery of Hereditary Breast and Ovarian Cancer Genetic Counseling

Condition: Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
The purpose of this research study is to assess the feasibility of performing hereditary breast and ovarian cancer genetic testing in the oncology clinic and to examine the knowledge and attitudes of hereditary breast and ovarian cancer genetic testing among breast and ovarian…
Read More

Study of Drug in Patients with Recurrent, Persistent or Metastatic Cervical Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination with Bevacizumab in Patients with Recurrent, Persistent or Metastatic Cervical Cancer. The purpose of this study is to test any good and bad effects of a combination of study drugs called atezolizumab and bevacizumab. The combination of atezolizumab and bevacizumab…
Read More

A study for women with breast cancer using a microfluidic device to detect leptomenigeal metastasis (LM)

Condition: Cancer / Breast Cancer
Investigator: Kevin Kalinsky, MD, MS
Status: Closed
This study is for women with breast cancer who will be undergoing lumbar puncture to evaluate for the presence of leptomeningeal metastasis, a complication in which the cancer spreads to the membranes (meninges) surrounding the brain and spinal cord. This condition is typically diagnosed by…
Read More

Study of Combination of Letrozole Plus Letrozole as Endocrine Therapy for Women with Breast Cancer

Condition: Cancer / Breast Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
The goal of this study is to determine if ribociclib in combination with letrozole as neoadjuvant endocrine therapy increases the proportion of women with PEPI score of 0 at surgery, compared to patients treated with letrozole alone therefore allowing more patients excellent outcomes without chemotherapy. The PEPI score measures the risk of breast…
Read More

Biomarker-Driven Study for Second Line Therapy of Squamous Cell Lung Cancer (Lung-MAP)

Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study screening step is to perform genetic tests on your tumor sample for certain features that investigational targeted agents used in this study are specifically designed to work against. Then the purpose is to assign you to a treatment sub-study that is chosen based on the results (genes and proteins called biomarkers) of this genetic…
Read More

A study for patients with non-small cell lung cancer (NSCLC) using study drug atezolizumab with standard chemotherapy to shrink tumors

Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This study is for patients who are being considered for surgical removal of a specific kind of lung cancer called "non-small lung cancer" (NSCLC), which is a description of the way it looks under a microscope. The purpose of this study is to determine whether adding an investigational treatment…
Read More

A study for women with invasive breast cancer or DCIS undergoing mastectomy using study drug Faslodex

Condition: Cancer / Breast Cancer
Investigator: Sheldon Feldman
Status: Closed
The main purpose of this study is to determine the safety and tolerability of Faslodex given directly into thebreast ducts of women with invasive breast cancer or Ductal Carcinoma In Situ (DCIS). This study is for women who have been diagnosed with invasive breast cancer or DCIS. DCIS is the…
Read More

Study of AZD4635 in Patients with Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Emerson Lim, MD
Status: Closed
The purpose of this study is to find a more effective treatment as well as to gain a better understanding of prostate cancer. This study includes investigational study drugs which are specific for your prostate cancer (module). Treatment in each module will include an investigational medication…
Read More

Pagination

  • Page 1
  • Next page ››
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science